Header Logo

Connection

DANIEL HAMSTRA to Humans

Back to Details
This is a "connection" page, showing publications DANIEL HAMSTRA has written about Humans.
DANIEL HAMSTRA
Connection Strength
1.091
Humans
  1. Bowel Disorder Incidence and Rectal Spacer Use in Patients With Prostate Cancer Undergoing Radiotherapy. JAMA Netw Open. 2025 Mar 03; 8(3):e250491.
    View in: PubMed
    Score: 0.026
  2. Hormonal status effects on the electrophysiological correlates of performance monitoring in women. Psychoneuroendocrinology. 2023 03; 149:106006.
    View in: PubMed
    Score: 0.022
  3. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy. Pract Radiat Oncol. 2023 Mar-Apr; 13(2):e166-e175.
    View in: PubMed
    Score: 0.022
  4. Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience. Int J Radiat Oncol Biol Phys. 2021 07 15; 110(4):1129-1131.
    View in: PubMed
    Score: 0.020
  5. Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):644-648.
    View in: PubMed
    Score: 0.019
  6. Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract Radiat Oncol. 2020 May - Jun; 10(3):186-194.
    View in: PubMed
    Score: 0.018
  7. Hypofractionation in Prostate Cancer Using Proton Beam. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):723-726.
    View in: PubMed
    Score: 0.018
  8. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 12; 141:137-143.
    View in: PubMed
    Score: 0.018
  9. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Am J Clin Oncol. 2019 04; 42(4):382-390.
    View in: PubMed
    Score: 0.017
  10. Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer. Lancet Oncol. 2018 10; 19(10):1275-1276.
    View in: PubMed
    Score: 0.017
  11. Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. Pract Radiat Oncol. 2019 Jan; 9(1):e22-e28.
    View in: PubMed
    Score: 0.017
  12. Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. Head Neck. 2018 07; 40(7):1375-1388.
    View in: PubMed
    Score: 0.016
  13. Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. Am J Clin Oncol. 2018 Jan; 41(1):6-12.
    View in: PubMed
    Score: 0.016
  14. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery. Oncology (Williston Park). 2017 11 15; 31(11):830-2, 835.
    View in: PubMed
    Score: 0.016
  15. Oral contraceptives positively affect mood in healthy PMS-free women: A longitudinal study. J Psychosom Res. 2017 12; 103:119-126.
    View in: PubMed
    Score: 0.016
  16. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):40-47.
    View in: PubMed
    Score: 0.015
  17. Don't Bet Against the Elderly. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):7.
    View in: PubMed
    Score: 0.015
  18. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352.
    View in: PubMed
    Score: 0.015
  19. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):e7-e15.
    View in: PubMed
    Score: 0.015
  20. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of?a?Phase III Trial. Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):976-985.
    View in: PubMed
    Score: 0.015
  21. Mineralocorticoid receptor haplotype, estradiol, progesterone and emotional information processing. Psychoneuroendocrinology. 2017 02; 76:162-173.
    View in: PubMed
    Score: 0.015
  22. Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing. J Psychopharmacol. 2016 10; 30(10):1054-61.
    View in: PubMed
    Score: 0.014
  23. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia. 2016 04; 18(4):213-22.
    View in: PubMed
    Score: 0.014
  24. Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol. 2015 Oct; 38(5):465-71.
    View in: PubMed
    Score: 0.014
  25. In Reply to King et al. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):937-9.
    View in: PubMed
    Score: 0.013
  26. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015 Aug; 38(4):367-72.
    View in: PubMed
    Score: 0.013
  27. Reply to G. Gandaglia et al and K. Lu. J Clin Oncol. 2015 Sep 01; 33(25):2833-4.
    View in: PubMed
    Score: 0.013
  28. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. Brachytherapy. 2015 Jul-Aug; 14(4):502-10.
    View in: PubMed
    Score: 0.013
  29. Ageism in the undertreatment of high-risk prostate cancer: how long will clinical practice patterns resist the weight of evidence? J Clin Oncol. 2015 Mar 01; 33(7):676-8.
    View in: PubMed
    Score: 0.013
  30. Mineralocorticoid receptor haplotype, oral contraceptives and emotional information processing. Neuroscience. 2015 Feb 12; 286:412-22.
    View in: PubMed
    Score: 0.013
  31. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol. 2014 Nov 26; 9:245.
    View in: PubMed
    Score: 0.013
  32. Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52.
    View in: PubMed
    Score: 0.013
  33. From the guest editor: Proton therapy: current evidence, challenges, and future plans. Cancer J. 2014 Nov-Dec; 20(6):369-70.
    View in: PubMed
    Score: 0.013
  34. The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making. 2015 01; 35(1):27-36.
    View in: PubMed
    Score: 0.013
  35. Oral contraceptives may alter the detection of emotions in facial expressions. Eur Neuropsychopharmacol. 2014 Nov; 24(11):1855-9.
    View in: PubMed
    Score: 0.013
  36. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):422-9.
    View in: PubMed
    Score: 0.012
  37. RE: Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst. 2014 Mar; 106(3):djt463.
    View in: PubMed
    Score: 0.012
  38. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol. 2014 Feb; 110(2):291-7.
    View in: PubMed
    Score: 0.012
  39. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014 Apr 01; 120(7):1076-82.
    View in: PubMed
    Score: 0.012
  40. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):721-8.
    View in: PubMed
    Score: 0.012
  41. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):554-61.
    View in: PubMed
    Score: 0.011
  42. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):546-53.
    View in: PubMed
    Score: 0.011
  43. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):64-71.
    View in: PubMed
    Score: 0.011
  44. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1246-53.
    View in: PubMed
    Score: 0.011
  45. Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265. J Urol. 2012 Dec; 188(6):2438-9; author reply 2439-40.
    View in: PubMed
    Score: 0.011
  46. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 2013 Feb 01; 119(3):681-90.
    View in: PubMed
    Score: 0.011
  47. The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. Radiat Oncol. 2012 Aug 01; 7:127.
    View in: PubMed
    Score: 0.011
  48. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. Radiat Oncol. 2012 Jun 09; 7:82.
    View in: PubMed
    Score: 0.011
  49. Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer. 2012 Apr 15; 118(8):2059-68.
    View in: PubMed
    Score: 0.010
  50. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e361-7.
    View in: PubMed
    Score: 0.010
  51. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol. 2011 Dec; 101(3):513-20.
    View in: PubMed
    Score: 0.010
  52. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e335-44.
    View in: PubMed
    Score: 0.010
  53. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e351-60.
    View in: PubMed
    Score: 0.010
  54. Outcomes of multidisciplinary management in pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e481-8.
    View in: PubMed
    Score: 0.010
  55. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1293-301.
    View in: PubMed
    Score: 0.010
  56. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e135-42.
    View in: PubMed
    Score: 0.010
  57. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 2010 Oct 01; 28(28):e518-9; author reply e521-e522.
    View in: PubMed
    Score: 0.009
  58. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res. 2010 May 01; 16(9):2666-76.
    View in: PubMed
    Score: 0.009
  59. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res. 2009 Jan 15; 15(2):589-96.
    View in: PubMed
    Score: 0.009
  60. Radiation therapy reduces local failure and improves overall survival in sPNET. Pediatr Blood Cancer. 2008 Jul; 51(1):148; author reply 149-50.
    View in: PubMed
    Score: 0.008
  61. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008 Jul 10; 26(20):3387-94.
    View in: PubMed
    Score: 0.008
  62. Revoking the privilege: targeting HER2 in the central nervous system. Mol Pharmacol. 2008 Feb; 73(2):271-3.
    View in: PubMed
    Score: 0.008
  63. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007 Sep 10; 25(26):4104-9.
    View in: PubMed
    Score: 0.008
  64. Primary radiotherapy for childhood ependymoma? Lancet Oncol. 2007 Sep; 8(9):758-9; author reply 760-1.
    View in: PubMed
    Score: 0.008
  65. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16759-64.
    View in: PubMed
    Score: 0.007
  66. Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol. 2005 Jul; 73(3):225-38.
    View in: PubMed
    Score: 0.007
  67. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747.
    View in: PubMed
    Score: 0.006
  68. Apparent diffusion coefficient values predict response to brachytherapy in bulky cervical cancer. Radiat Oncol. 2024 Mar 13; 19(1):35.
    View in: PubMed
    Score: 0.006
  69. Testicular Dysfunction in Male Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2024 Jun 01; 119(2):610-624.
    View in: PubMed
    Score: 0.006
  70. Stereotactic Body Radiation Therapy vs Surgery for Early-Stage Non-Small Cell Lung Cancer: Does the Dealer Influence the Choice? Ann Thorac Surg. 2023 02; 115(2):354-355.
    View in: PubMed
    Score: 0.005
  71. Two Specialists, Two Recommendations: Discordance Between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. Urology. 2022 11; 169:156-161.
    View in: PubMed
    Score: 0.005
  72. Oral D-methionine protects against cisplatin-induced hearing loss in humans: phase 2 randomized clinical trial in India. Int J Audiol. 2022 08; 61(8):621-631.
    View in: PubMed
    Score: 0.005
  73. Preparing Patients with Early Stage Prostate Cancer to Participate in Clinical Appointments Using a Shared Decision Making Training Video. Med Decis Making. 2022 04; 42(3):364-374.
    View in: PubMed
    Score: 0.005
  74. Ethical Allocation of Proton Therapy and the Insurance Review Process. Pract Radiat Oncol. 2021 Sep-Oct; 11(5):e449-e458.
    View in: PubMed
    Score: 0.005
  75. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. BJU Int. 2020 09; 126(3):367-372.
    View in: PubMed
    Score: 0.005
  76. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res. 2000 Feb 01; 60(3):657-65.
    View in: PubMed
    Score: 0.005
  77. VA-Radiation Oncology Quality Surveillance Program. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):639-647.
    View in: PubMed
    Score: 0.005
  78. Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology, and end results analysis. Pediatr Blood Cancer. 2019 12; 66(12):e27969.
    View in: PubMed
    Score: 0.004
  79. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 01 20; 37(3):213-221.
    View in: PubMed
    Score: 0.004
  80. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018 06 14; 4(6):e180039.
    View in: PubMed
    Score: 0.004
  81. Changes in prostate orientation due to removal of a Foley catheter. Med Phys. 2018 Apr; 45(4):1369-1378.
    View in: PubMed
    Score: 0.004
  82. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386.
    View in: PubMed
    Score: 0.004
  83. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology. 2018 May; 115:39-44.
    View in: PubMed
    Score: 0.004
  84. Knowledge-based treatment planning and its potential role in the transition between treatment planning systems. Med Dosim. 2018 Autumn; 43(3):251-257.
    View in: PubMed
    Score: 0.004
  85. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68.
    View in: PubMed
    Score: 0.004
  86. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357.
    View in: PubMed
    Score: 0.004
  87. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):304-317.
    View in: PubMed
    Score: 0.004
  88. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017 05 01; 123(9):1635-1642.
    View in: PubMed
    Score: 0.004
  89. Brainstem Low-Grade Gliomas in Children-Excellent Outcomes With Multimodality Therapy. J Child Neurol. 2017 02; 32(2):194-203.
    View in: PubMed
    Score: 0.004
  90. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016 11; 121(2):193-198.
    View in: PubMed
    Score: 0.004
  91. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053.
    View in: PubMed
    Score: 0.004
  92. Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol. 2017 02; 197(2):376-384.
    View in: PubMed
    Score: 0.004
  93. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):770-777.
    View in: PubMed
    Score: 0.004
  94. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 10; 34(10):430.e1-7.
    View in: PubMed
    Score: 0.004
  95. Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016 09; 19(3):292-7.
    View in: PubMed
    Score: 0.004
  96. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):173-80.
    View in: PubMed
    Score: 0.004
  97. Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):181-8.
    View in: PubMed
    Score: 0.004
  98. Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2016 09; 118(3):372-8.
    View in: PubMed
    Score: 0.003
  99. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249.
    View in: PubMed
    Score: 0.003
  100. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84.
    View in: PubMed
    Score: 0.003
  101. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 01; 93(2):294-302.
    View in: PubMed
    Score: 0.003
  102. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2016 Jan; 69(1):50-7.
    View in: PubMed
    Score: 0.003
  103. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):229-36.
    View in: PubMed
    Score: 0.003
  104. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric?and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate?Image Guided Intensity Modulated Radiation?Therapy. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):971-977.
    View in: PubMed
    Score: 0.003
  105. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015 Mar; 67(3):460-7.
    View in: PubMed
    Score: 0.003
  106. Osteochondromas after radiation for pediatric malignancies: a role for expanded counseling for skeletal side effects. J Pediatr Orthop. 2014 Apr-May; 34(3):331-5.
    View in: PubMed
    Score: 0.003
  107. Complications of prostate cancer treatment. Lancet Oncol. 2014 Apr; 15(4):e150.
    View in: PubMed
    Score: 0.003
  108. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology. 2013 Dec; 82(6):1363-8.
    View in: PubMed
    Score: 0.003
  109. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat Oncol. 2013 Aug 21; 8:204.
    View in: PubMed
    Score: 0.003
  110. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):275-81.
    View in: PubMed
    Score: 0.003
  111. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):99-107.
    View in: PubMed
    Score: 0.003
  112. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol. 2013 Jul 08; 8:170.
    View in: PubMed
    Score: 0.003
  113. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer. 2013 Sep 15; 119(18):3287-94.
    View in: PubMed
    Score: 0.003
  114. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35.
    View in: PubMed
    Score: 0.003
  115. The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):230-6.
    View in: PubMed
    Score: 0.003
  116. Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer. Med Dosim. 2012; 37(3):240-4.
    View in: PubMed
    Score: 0.003
  117. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):940-6.
    View in: PubMed
    Score: 0.003
  118. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
    View in: PubMed
    Score: 0.003
  119. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res. 2011 Jul 15; 17(14):4751-60.
    View in: PubMed
    Score: 0.002
  120. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev. 2011 Apr; 37(2):89-96.
    View in: PubMed
    Score: 0.002
  121. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology (Williston Park). 2010 Jul; 24(8):692-700, 702.
    View in: PubMed
    Score: 0.002
  122. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010 May 01; 28(13):2293-9.
    View in: PubMed
    Score: 0.002
  123. Counseling patients about sexual health when considering post-prostatectomy radiation treatment. Int J Impot Res. 2009 Sep-Oct; 21(5):275-84.
    View in: PubMed
    Score: 0.002
  124. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009 May; 15(5):572-6.
    View in: PubMed
    Score: 0.002
  125. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res. 2008 Apr 01; 14(7):2161-70.
    View in: PubMed
    Score: 0.002
  126. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res. 2007 Mar 15; 13(6):1839-46.
    View in: PubMed
    Score: 0.002
  127. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006 Sep 01; 66(17):8912-7.
    View in: PubMed
    Score: 0.002
  128. Imaging of proteolytic activity using a conditional cell surface receptor. Mol Imaging. 2006 Apr-Jun; 5(2):129-37.
    View in: PubMed
    Score: 0.002
  129. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther. 2006 Jan; 13(2):127-37.
    View in: PubMed
    Score: 0.002
  130. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16551-5.
    View in: PubMed
    Score: 0.001
  131. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000 Feb 15; 97(4):1754-9.
    View in: PubMed
    Score: 0.001
  132. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998 Mar 01; 101(5):1102-10.
    View in: PubMed
    Score: 0.001
  133. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997 Dec 15; 57(24):5571-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.